USA - engelsk - NLM (National Library of Medicine)

biogen inc. - natalizumab (unii: 3jb47n2q2p) (natalizumab - unii:3jb47n2q2p) - natalizumab 300 mg in 15 ml - tysabri is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. tysabri increases the risk of pml [see warnings and precautions (5.1) ]. when initiating and continuing treatment with tysabri, physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk. tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional cd therapies and inhibitors of tnf-α. tysabri should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of tnf-α [see warnings and precautions (5.1) ]. - tysabri is contraindicated in patients who have or have had progressive mult

USA - engelsk - NLM (National Library of Medicine)

therabiogen - green tea leaf (unii: w2zu1ry8b0) (green tea leaf - unii:w2zu1ry8b0), sambucus nigra flowering top (unii: ct03bsa18u) (sambucus nigra flowering top - unii:ct03bsa18u), gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - green tea leaf 3 [hp_x] in 15 ml - purpose cold and flu symptom relief uses relieves old and flu symptoms provides relief from upper respiratory symptoms such as nasal and sinus congestion, runny nose, sore throat, sneezing and headache also relieves fever, chills and body aches associated with the flu stop use and ask a doctor if symptoms persist

USA - engelsk - NLM (National Library of Medicine)

biogen inc. - peginterferon beta-1a (unii: i8309403r0) (peginterferon beta-1a - unii:i8309403r0) - peginterferon beta-1a 94 ug in 0.5 ml - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. plegridy is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of plegridy [see warnings and precautions ( 5.3)] . risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interferon beta during pregnancy resulted in an increased rate of abortion (see data ). in the u.s. general population, the estimated backgro

USA - engelsk - NLM (National Library of Medicine)

biogen inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 30 ug in 0.5 ml - avonex is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see warnings and precautions (5.3)] . the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human). risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interfer

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

biogen idec iberia s.l. - naproxeno - granulado - 500 mg - naproxeno 500 mg - naproxeno

USA - engelsk - NLM (National Library of Medicine)

biogen inc. - aducanumab (unii: 105j35oe21) (aducanumab - unii:105j35oe21) - aduhelm is indicated for the treatment of alzheimer's disease. treatment with aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. this indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with aduhelm [see clinical studies (14)] . continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). none. risk summary there are no adequate data on aduhelm use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. dat

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abiogen pharma s.p.a. via meucci, 36 56121 pisa (italiË) - etoricoxib 120 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; titaandioxide (e 171)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abiogen pharma s.p.a. via meucci, 36 56121 pisa (italiË) - etoricoxib 30 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; titaandioxide (e 171)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abiogen pharma s.p.a. via meucci, 36 56121 pisa (italiË) - etoricoxib 60 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; titaandioxide (e 171)

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

abiogen pharma s.p.a. via meucci, 36 56121 pisa (italiË) - etoricoxib 90 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; magnesiumstearaat (e 470b) ; titaandioxide (e 171)